NHS chief executive Amanda Pritchard today (March 1) announced a new campaign to promote early detection of cancer, when it is easier to treat.
The campaign, which would run across TV, radio, and social media from Wednesday (March 2), is the first to focus on tackling the fear of cancer rather thanspecific symptoms.
It is in line with the NHS Long Term Plan's commitment to increase cancer detection at an early stage by 2028.
As per the NHS figures, the number of people getting checked for cancer increased by over half a million between December 2020 and December 2021.
Speaking ahead of the launch, Pritchard, said: "We know that the prospect of a cancer diagnosis can be daunting for people and that is exactly why we are launching this potentially lifesaving campaign - we want to allay people's fear about cancer and encourage them to get checked without delay.
Superdrug has unveiled its new fertility test service to help women to easily access information about their own fertility and enables them to take greater control of their reproductive health.
The service comprises a Superdrug online doctor consultation and personalised fertility test recommendations to help women make more informed decisions about the options available to them.
Superdrug's fertility test initial consultation requires customers to fill out a quick online questionnaire. This is then reviewed by Superdrug's team of online doctors, who will work with the patients to identify which fertility tests are best suited to the individual. The new service also sees Superdrug introduce three new fertility blood tests to its portfolio, ensuring greater choice and accessibility.
Dr Sara Kayat, Superdrug's medical ambassador comments, "For women that have been trying to get pregnant and not succeeding, or for those who are just curious about their fertility, easy access to blood tests may help provide answers and signpost them in the right direction."
The Department of Health and Social Care (DHSC) has announced 30 pence increase in prescription charges from £9.35 to £9.65 for each medicine or appliance
dispensed.
Board Chair for England at RPS, Thorrun Govind commented: "This is a kick in the teeth for people in England who are already struggling with rising bills and food
prices.
"Patients groups have warned that people are not collecting prescription medicines due to cost and pharmacists are seeing this worrying trend first-hand.
"A Government impact assessment noted the risk of adverse effects of people not taking their medicines, resulting in future health problems for the individual,
potential hospital admissions, and a subsequent cost to the NHS.
"This decision seems to prioritise revenue generation over ill-health prevention and undermines the principle of an NHS free at the point of use.
A new, independent search engine has launched called Vitaminology which enables the search, discovery and comparison of vitamins and supplements to empower
consumers to make more informed choices and find the right products for their personal health goals and requirements.
The company has set out to reduce confusion in this market through choice and high-quality information as well as access to one-to-one consultations with accredited
nutritional therapists. By offering the complete package of advice, resources and products Vitaminology helps people to lead healthier lives.
Mike Murphy, who is chief nutritionist for Vitaminology, comments, "This innovative platform has a powerful comparison and filtering feature that helps to simplify
the choices available for consumers so they can make better self-care decisions. This is supported by access to video consultations with nutritional therapists as
well as a comprehensive library of ingredient profiles, articles clustered around health conditions and unique recipes to support wellness."
AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with
advanced ovarian cancer.
The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free
survival in newly diagnosed patients with advanced ovarian cancer without certain mutations.
Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with
chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added.
Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial,
said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for
the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community."
Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an
unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour
BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary
endpoints as well as data for relevant subgroups."
The Medicines and Healthcare products Regulatory Agency (MHRA) has advised 'no one should stop taking valproate without advice from their healthcare
professional.'
The latest data on the use of valproate in England revealed that in the last 6 months the number of pregnant women prescribed valproate in a 6-month period has
fallen from 68 women in April to September 2018, to 17 women in October 2021 to March 2022.
In light of concerns that the current regulatory requirements for safe use are not being consistently followed, the MHRA conducted a review of the available data
and asked for advice from the independent Commission on Human Medicines (CHM).
"The CHM has advised that no one under the age of 55 should be initiated on valproate unless two specialists independently consider and document that there is no
other effective or tolerated treatment," said MHRA.
"Where possible, existing patients should be switched to another treatment unless two specialists independently consider and document that there is no other effective
or tolerated treatment or the risks do not apply."
Product packaging affects the effectiveness of pharmaceuticals to a great extent. This is why pharmaceutical companies ensure they choose appropriate packaging
for drug products. Drug packaging is not always an easy job. However, the tips in this article will help you select the proper pharmaceutical packaging for drug
products without stress.
What Does Pharmaceutical Packaging Entail?
Pharmaceutical packaging involves using packaging containers with safety closures such as a lidding film to hold pharmaceutical products. This is done to keep them
safe and effective.
The most commonly used packaging materials in the pharmaceutical industry are metals, glass, and plastics. These materials are used for different reasons and
different products. In short, a pharmacist considers several factors regarding a product and its target audience before choosing a packaging material for
pharmaceutical formation.
Why Appropriate Packaging Matters
Many benefits come with appropriate pharmaceutical packaging. These benefits make it essential to package drug products in the best ways possible. When pharmaceutical
items are properly packed, they can reach patients for a safe prescription. As a result, the drug stands a higher chance of achieving its prescription purpose. More
so, properly packaged drug products are safer to consume and can be trusted.
The Pharmacists' Defence Association (PDA) has undertaken an additional survey of pharmacists employed in the NHS, before deciding to hold their first-ever
ballot for industrial action.
The PDA has more than 7,000 NHS-employed pharmacists in membership and the union is actively considering balloting those members regarding strike action.
The association said: "The experience of some other unions has shown that the government's restrictive rules, designed to make it difficult for working people to
lawfully take industrial action, means trade unions should test members' strength of feeling before balloting."
"Trade unions are not only forced to rely upon postal ballots, but for lawful industrial action to be taken, the result must also meet three tests- at least 50% of
eligible voters must vote; at least 40% of eligible voters must vote 'yes' and a majority of votes must be for 'yes'."
The association is asking members in England, Northern Ireland and, Wales to show if their collective wish, insignificant enough strength, is for strike action. PDA
has emailed the survey to all its members in the NHS in the three nations and will close on Tuesday 3 January.
Chiesi Farmaceutici, the international, research-focused biopharmaceuticals and healthcare group has acquired Amryt Pharma, a global biopharmaceutical company
dedicated to developing novel treatments for rare diseases.
More than 300 million people worldwide are affected by rare diseases, including those who are living with ultra-rare metabolic and dermatologic conditions who still
have no approved treatment.
The acquisition reinforces Chiesi's commitment to deliver innovative treatments to patients with highly unmet medical needs. As a benefit corporation and a B Corp,
Chiesi strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet.
Chiesi's Head of Chiesi Global Rare diseases Giacomo Chiesi commented: "We are excited to add the Amryt family to our company in this acquisition that demonstrates
our commitment to rare diseases and aligns with our growth strategy through partnerships beyond internal research and development."
Chiesi's new CEO Giuseppe Accogli said: "By joining forces and expertise we will be able to grow our capabilities and further strengthen our position to provide a
positive impact on patients living with rare diseases."
With regard to the financing of the deal, cash consideration has been partially financed through a EUR 700m syndicated loan led by BNP Paribas and Crédit Agricole
as Global Coordinators and ESG Structuring Banks, acting alongside BPER and Deutsche Bank as Mandated Lead Arrangers. Crédit Agricole is Loan Agent too. Lenders have
been advised by Clifford Chance, while Baker and McKenzie has assisted Chiesi Farmaceutici.
In recent years, there has been an increased focus on the importance of health. People are looking for ways to improve their health and live a longer, more
productive life. There are many different places that people can go to work on their health, but some are better than others. Here is a list of the top six places
to work on your health.
1) MEDICAL SPA
A medical spa is a place where people can go to improve their health. medical spas offer a variety of services, including skin care, laser hair removal, and body
contouring. They also offer a variety of medical treatments, such as laser surgery and Botox injections.
Medical spas offer a number of benefits to their patients. First, they offer a wide variety of services that can help people improve their health. Second, they offer
a number of medical treatments that can help people address specific health concerns. Third, they offer a relaxing environment where people can come to improve their
health and wellbeing. No matter if you're looking for a medical spa in Alexandria, VA, New York, or any other state, they can be a great place to work on your health.
Plus, if you're looking for a place to get health insurance, they can also help you with that.
Thanks for sharing this! I started monitoring my health only when it became necessary. I am very overweight. I think buy wegovy online ( https://www.canadadrugsdirect.com/products/wegovy ) on the recommendation of a doctor. Also, I have already signed up to the gym for individual classes and also for fitness. I started to eat properly and am constantly looking for good new recipes that I can repeat at home
Darren Jones MP, the Shadow Chief Secretary to the Treasury, visited Sigma Pharmaceuticals plc's new Watford facility on Thursday (6 June) as part of the
imminent Labour Party campaign trail.
Jones was joined by Labour's prospective parliamentary candidate for Watford, Matt Turmaine, and a team of campaign workers.
During their visit, the Labour delegation met with the directors and founding member of Sigma, Dr Bharat Shah CBE, and discussed the importance of investment
and support for growing businesses and the pharmaceutical sector both in the region and across the country.
Sigma Pharmaceuticals, which is believed to be Watford's largest employer, noted that the pharmaceutical sector contributes a significant value to the East of
England, accounting for 12.3 per cent of the region's manufacturing gross value added (GVA).
